Literature DB >> 10331969

CD44 modulates Hs578T human breast cancer cell adhesion, migration, and invasiveness.

A Herrera-Gayol1, S Jothy.   

Abstract

CD44 is an adhesion molecule that has been implicated in tumor progression of epithelial and nonepithelial tumors. One of its variants, CD44v6, is involved in the production of experimental metastasis. Previous reports have indicated that in human breast cancer the overexpression of CD44, and moreover the presence of CD44v6, correlated with poor prognosis. This study focuses on the role of these molecules in in vitro invasion of breast cancer cells. The effect of antibodies against all CD44 isoforms and CD44v6 was evaluated in different in vitro experimental assays that are closely related to tumor cell invasion in vivo: adhesion to hyaluronan and purified extracellular matrix components; cell motility; haptotaxis; and invasion of purified extracellular matrix components. The highly metastatic human breast cancer cell line Hs578T was used in all assays. Our results show that both antibodies have a blocking effect on cell migration, on haptotatic migration, on in vitro invasion, and on adhesion to hyaluronan and purified extracellular matrix components. In conclusion, our data show that, in addition to its participation in adhesion to components of the extracellular matrix, CD44v6 is involved in the motility and in invasion of tumoral cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331969     DOI: 10.1006/exmp.1999.2236

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  13 in total

1.  Effects of hyaluronan on the invasive properties of human breast cancer cells in vitro.

Authors:  A Herrera-Gayol; S Jothy
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

Review 2.  The role of osteopontin in breast cancer: clinical and experimental studies.

Authors:  A B Tuck; A F Chambers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

3.  Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.

Authors:  Yanping Chen; Jinlian Song; Yuhong Jiang; Chundong Yu; Zhongliang Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers.

Authors:  Rachael C Casey; Kimberly A Koch; Theodore R Oegema; Keith M Skubitz; Stefan E Pambuccian; Suzanne M Grindle; Amy P N Skubitz
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  TNFalpha and IL-8 regulate the expression and function of CD44 variant proteins in human colon carcinoma cells.

Authors:  Michal Barshishat; Amiram Ariel; Liora Cahalon; Yehuda Chowers; Ofer Lider; Betty Schwartz
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 6.  Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

7.  Butyrate down-regulates CD44 transcription and liver colonisation in a highly metastatic human colon carcinoma cell line.

Authors:  M Barshishat; I Levi; D Benharroch; B Schwartz
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

Review 8.  The role of CD44 in epithelial-mesenchymal transition and cancer development.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Hua Wu; Qian Liu; Richard G Pestell; Kongming Wu
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

9.  CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration.

Authors:  Ke Zen; Dan-Qing Liu; Ya-Lan Guo; Chen Wang; Jun Shan; Ming Fang; Chen-Yu Zhang; Yuan Liu
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

Review 10.  Rafting Down the Metastatic Cascade: The Role of Lipid Rafts in Cancer Metastasis, Cell Death, and Clinical Outcomes.

Authors:  Joshua D Greenlee; Tejas Subramanian; Kevin Liu; Michael R King
Journal:  Cancer Res       Date:  2020-09-30       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.